Highline Capital Management, founded in 1995, conducts fundamental research to create portfolios with attractive risk/return profiles, priding itself on a successful track record in the U.S. equity market. The firm primarily invests in startups that are one year old or less, with a particular interest in the biotechnology industry. They typically participate in funding rounds with more than 10 other investors and often collaborate with sponsors like Vivo Capital, Versant Ventures, and OrbiMed. While the fund is involved in fewer than two deals per year, it tends to focus on deals exceeding $100 million.